期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 16, 期 9, 页码 1087-1092出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2016.1195264
关键词
Antiepileptic drugs; epilepsy; lacosamide; eslicarbazepine acetate; brivaracetam; monotherapy; FDA; license; treatment
资金
- UCB Pharma
- Eisai
- Pfizer
- Elsevier
- Bial and Special Products Ltd.
Introduction: Drugs marketed during the last few years (i.e. Lacosamide, Ruifinamide, Eslicarbazepine acetate, Brivaracetam and Perampanel) are increasingly regarded as third generation AEDs. This paper presents available data about monotherapy with third generation drugs and on-going clinical trials with special attention to the existing debate about monotherapy license in epilepsy.Areas covered: References were identified by searches of Medline/PubMed. In addition, currently active studies for these AEDs were identified in the ClinicalTrials.gov database.Expert commentary: Results of studies on Eslicarbazepine acetate and Lacosamide clearly suggest good efficacy and tolerability. The selective pharmacological profile, the lack of interactions, the good tolerability with low propensity for cognitive side effects and the availability of different pharmacological formulations represent evident advantages. Although third generation monotherapies are quite promising, long-term safety data is needed in order to understand how these compounds will place in the current armamentarium.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据